Background Patients with atrial fibrillation (AF) can be severely incapacitated by symptoms, but validated symptom measures are lacking. The aim of this study was to develop an AF-specific symptom questionnaire (AFSymp   TM   ) . Methods Following a literature review, qualitative interviews with 91 patients (United States [US], n = 30; United Kingdom [UK], n = 16; France, n = 15; Germany, n = 15; Japan, n = 15) with paroxysmal, persistent, and permanent AF were conducted to identify emergent concepts and to develop the items and response options for the AFSymp TM . Clinical experts (n = 21) in the US, the UK, France, Germany, and Japan provided feedback on the most clinically relevant symptoms via an email survey. Cognitive interviews with 30 patients were conducted to evaluate content validity. A prospective, observational, psychometric evaluation study (n = 313) consisting of two study visits was performed at 32 sites across the US.
Background
Atrial fibrillation (AF) is the most common cardiac condition, with prevalence estimates of 1 % among patients younger than 60 years and 8 % among those older than 80 years [1] . Symptoms and their impact on domains of patients' daily lives are best measured through direct report by patients themselves. Studies of AF symptoms and their health-related quality of life (HR-QOL) impact have most often used the generic Short Form-36 (SF-36) [2] or EuroQoL Five Dimension (EQ-5D) [3] , which are not always sensitive to impairments resulting from AF [4] . There are also a number of condition-specific tools [5] [6] [7] [8] that evaluate a range of symptoms and AF impacts. However, many of these were not developed in a manner that would satisfy contemporary regulatory standards [7, 8] , while others designed to assess symptoms and HR-QOL impact may be too lengthy for routine use. Thus, there is a need for a tool specifically designed to assess AF symptoms in the context of research and clinical practice. The aim of this manuscript is to describe the development of the AFSymp TM , a new, AF-specific symptom measure developed to evaluate AF symptoms and suitable for use in multiple languages and cultural contexts and to meet contemporary regulatory standards [7, 8] .
Methods
The development and validation of the AFSymp TM was conducted in two phases consisting of qualitative and quantitative research (Fig. 1) . Independent Research Board approval was obtained prior to initiation of data collection and all participants provided written informed consent. A second instrument-the AFImpact TM score-was developed concurrently to assess the impact of AF-related symptoms on domains of HR-QOL following these research activities and will be described in a separate article.
Phase I: Concept Elicitation, Instrument
Development, and Cognitive Interviewing
The development of the instrument involved a review of the literature and in-depth qualitative research. Peerreviewed articles on non-valvular AF and atrial flutter were reviewed to identify existing patient-reported outcome (PRO) measures. In-depth, qualitative, concept elicitation interviews were conducted with 91 patients (United States [US], n = 30; United Kingdom [UK], n = 16; France, n = 15; Germany, n = 15; Japan, n = 15) identified from clinical sites with confirmed diagnosis of paroxysmal, persistent and permanent AF (n = 30, 30 and 31, respectively) to explore the range of AF symptom experiences. AFSymp atrial fibrillation-specific symptom questionnaire, ePRO electronic patient-reported outcome, UK United Kingdom, US United States Interviews were conducted by experienced, trained interviewers native to the respective countries following a standardized interview guide and audio recorded with participants' permission.
Interviews started with openended questions (e.g., ''Tell me about a typical day with your atrial fibrillation''), with more specific direct questioning only used if concepts of interest did not arise. The qualitative data were transcribed verbatim and analyzed in the native language using thematic analysis techniques to identify emergent concepts and to provide qualitative content to support the development of the items for the AFSymp TM using natural patient language. Feedback from expert clinicians regarding the most relevant symptoms to assess for each AF subtype was then obtained via an e-mail survey administered to 21 clinicians in the US (n = 5), the UK (n = 3), France (n = 2), Germany (n = 5), and Japan (n = 6) [9] .
Following the development of the initial draft AFSymp TM , cognitive interviews were conducted to further evaluate content validity and determine the interpretability, comprehension, and ease of use of the instrument. Thirty patients in the US (ten paroxysmal, ten persistent, ten permanent) were recruited through three clinicians. Twenty participants were administered the questionnaires in an electronic PRO (ePRO) format, and ten were administered in a pen/paper format. All participants were asked the same questions regarding the length, comprehensiveness, and format of the questionnaires as well as specific questions about their understanding and the relevance of each item.
Phase II: Psychometric Evaluation
After development of the AFSymp TM in Phase I, a prospective, observational psychometric evaluation study consisting of two study visits, baseline and 14 ± 3 days later, without any investigational medications or procedures, was performed at 32 sites across the US using the ePRO version of the AFSymp TM . Patients with symptomatic AF were recruited through 32 clinical sites in the US and screened by clinical staff to determine study eligibility. Inclusion criteria included age 18-80 years, paroxysmal, persistent or permanent AF with symptoms in the past 7 days, ability to read and complete questionnaires on the electronic device, and provision of written informed consent. At baseline, the AFSymp TM and other PRO instruments were completed: the SF-36 (1-week recall period) [10] [11] [12] [13] [14] , the Toronto Atrial Fibrillation Severity Scale (AFSS) (a 19-item, disease-specific measure developed to capture patient ratings of frequency, duration and severity of episodes) [9, 15] , and the AFImpact TM . At follow-up, the overall treatment effect (OTE), an instrument with three items addressing whether a patient had improved or deteriorated since last visit [16] , was administered together with the AFSymp TM and AFImpact TM . As part of the OTE, if patients indicated an improvement or deterioration, they were asked to score the magnitude and the importance of the experienced change on a 7-graded scale.
Statistical Analyses
All analyses were performed on Statistical Analysis System (SAS), version 8.0 and 9.1.3 software [17] , except for Rasch analysis which was performed using Rasch Unidimensional Model Measurement (RUMM), version 3.1 software [18] . Rasch analysis and exploratory and confirmatory factor analyses (EFA, CFA) were used to reduce the items and uncover subscales to inform the scoring for the instrument. Descriptive statistics were used to summarize sample demographic and clinical characteristics.
Internal consistency reliability was assessed using Cronbach's formula for coefficient alpha [19] . Test-retest reliability was assessed in patients whose status was considered stable (defined as patients who reported that their health was ''about the same'' on the OTE questionnaire at study Visit 2).
Construct validity was assessed by examining Pearson's correlations between the domain scores of the AFSymp TM and those of SF-36 and AFSS at baseline. Convergent validity is supported when scale score correlations are of magnitude r C 0.30 with items or scales measuring similar concepts, while divergent validity is supported by low correlations between theoretically unrelated dimensions [20] .
Values [ 0.70 were considered acceptable for estimates of internal consistency reliability and test-retest reliability and Pearson's correlations and intra-class correlations (ICC), while values exceeding the more conservative 0.80 threshold were considered strong [21] .
Known-groups validity was assessed by comparing AFSymp TM scores among groups of patients who differed according to the physician-rated severity of their AF symptoms and according to patient reported AF status (currently in AF or not according to item 3 of the AFSS). Analysis of variance (ANOVA) was used for comparisons among groups with Scheffe's adjustment for post hoc pairwise comparisons.
Results

Phase I: Concept Elicitation, Instrument
Development, and Evaluation of Content Validity
The in-depth qualitative interviews included 60 (66 %) male and 31 (34 %) female AF patients aged \60 (27%), 60-69 (30 %) and [69 (44 %) years. All patients were currently receiving medication for their AF, and the majority (79 %) had a comorbid condition, with hypertension being the most common (43 %). A number of themes emerged across the multi-country qualitative interviews. The most commonly reported symptoms in all countries were fatigue, shortness of breath, and awareness of sensations in the heart including a rapid heartbeat, a pounding heartbeat, a skipping heartbeat, an irregular heartbeat, a slow heartbeat, and palpitations. Other less commonly reported symptoms included chest pain, dizziness, feeling faint, and shaking/trembling. A feeling of anxiety or 'a panic feeling' was also described. In terms of the impact on patients' activities of daily living, patients found that they had to stop to rest more often during daily activities and consequently took longer to get things done. All patients reported that their level of energy was impacted. Common descriptions included becoming tired or fatiguing easily, lacking energy, and falling asleep during the day. AF symptoms that were consistently identified in the literature review, qualitative interviews, and expert clinician survey were used to generate 28 items in US English for the AFSymp TM . All items were worded using terms used by patients in order to maximize ease of understanding. Table 1 illustrates the process of mapping representative patient quotations to items by showing the development of one item. Based on the qualitative patient data, a 1-week recall period and seven-point categorical response scale (none of the time, hardly any of the time, a little of the time, some of the time, a good bit of the time, most of the time, all of the time) [19, 20] were selected. After the development of the initial item bank, cognitive interviews were conducted with 17 (57 %) male and 13 (43 %) female patients with demographic and clinical characteristics similar to that of the in-depth qualitative study sample (data on file). Both the pen/paper and ePRO versions of the questionnaire (Dana, Invivo Data Inc.) were generally reported to be clear and equally easy to use by most patients. Patient feedback resulted in minor revisions to the wording of nine of the items to improve clarity. Two items (feeling lethargic and cold sweats) were deleted because of difficulties in comprehension and ambiguous interpretation.
Phase II: Psychometric Evaluation
A total of 313 AF patients were enrolled in the psychometric evaluation study (103 with paroxysmal AF, 100 with persistent AF, and 110 with permanent AF). The majority of patients were men (60 %), with a mean age of 65 years (range 25-80; Table 2 ).
Item Reduction and Scoring Algorithm
None of the patients in the psychometric evaluation study had any missing data for the AFSymp TM questionnaires. This was most likely due to the electronic format, which prevented skipping of items. Frequency distributions and Rasch analysis identified items with unfavorable response distributions (heavily skewed distributions, relevant floorceiling effects, or bi-modal distributions) or inability of patients to distinguish among response options. Items were eliminated if they could not be systematically assigned to a unidimensional scale, if they had a high floor or ceiling effect ([70 % scoring at floor or ceiling) or if they correlated highly with other items, indicating redundancy. The clinical importance of the items based on the clinical expert feedback and qualitative data obtained in Phase I also guided decisions about item retention/deletion. Of the 28 items that were tested during this process, 17 were deleted due to the reasons noted above. Thus, the final version of the AFSymp TM consists of 11 items. Results of the EFA and CFA derived and confirmed the appropriateness of three subscales: heart symptoms (four items), tiredness (three items), and chest discomfort (two items). A single global score was also developed, consisting of the seven AF symptoms that were experienced most frequently by patients and were considered most reflective of AF symptoms according to clinicians. Additionally, two items measuring dizziness and shortness of breath were each scored as single items and not included in the single global score or any of the three subscales. The seven-item global AFSymp TM scale was found to fit the data very well as a hierarchical latent model with excellent fit indices ( Table 3 ). The tiredness subscale exceeded all fit parameters, while the heart symptoms subscale exceeded two of the three fit parameters (Bentler's Confirmatory Fit Index and standardized root mean square residual [SRMR] ). The chest discomfort subscale, which contains two items, was an over-identified model which was difficult to fit. Importantly, a model's fit need not meet all pre-designated parameters to be deemed acceptable when the scaling is clinically relevant and important to patients [17] . A copy of the instrument and scoring instructions are provided in the electronic supplementary material A and B.
Reliability
Cronbach's alpha coefficients demonstrated strong internal consistency for the multi-item subscale domains and total score: 0.91 (tiredness-three items), 0.82 (heart symptoms-four items), 0.79 (chest discomfort-two items) and 0.87 (single global score). The test-retest reliability (ICC) of the AFSymp TM individual items and subscales in stable patients as defined by OTE was acceptable, with ICCs ranging from 0.58 (item 4, feel weak) to 0.78 (item 9, feel lack of energy) ( Table 4 ). The AFSymp TM seven-item global score demonstrated strong reproducibility with an ICC coefficient of 0.78, as did the three multi-item subscale scores: heart symptoms (ICC = 0.74), tiredness (ICC = 0.77), and chest discomfort (ICC = 0.76).
Construct Validity
Convergent and Discriminant Validity
Correlations among the SF-36 and the AFSymp TM subscales showed that these concepts behaved as expected in relation to one another (r range = -0.38 to 0.72; all p \ 0.0001). Scales measuring similar concepts correlated more highly (convergent validity) than scales measuring dissimilar concepts (divergent validity) (e.g., the SF-36 vitality scale correlated more highly with AFSymp TM tiredness than with heart symptoms, r = -0.68 and r = -0.41, respectively) (data on file). The correlations of the AFSymp TM with the AFSS subscales ranged between 0.55 and 0.67 in scales measuring similar concepts.
Known-Groups Validity
The seven-item single global score and all subscales, with the exception of chest discomfort scale and dizziness item, differentiated between patients who stated they were currently in AF versus those who were not in AF at statistically significant levels. Patients currently in AF had significantly higher mean AFSymp TM seven-item global score than patients not currently in AF (mean scores of 3.4 vs 2.9, p \ 0.0001, respectively). Similar trends were also present in the subscales with the exception of chest discomfort where there was no significant difference between the two groups. Known-groups validity was also examined by comparison of scores by clinician report of severity.
Patients with more clinically severe AF reported significantly higher mean subscale scores than patients with mild to moderate symptoms (Table 5 ).
Discussion
Results presented here support the AFSymp TM as a comprehensive measure of AF-related symptoms with evidence of content validity and psychometric validity and reliability. This 11-item instrument covers five domains and includes one single global score. The instrument's simple format and brevity (taking less than 5 minutes to complete) make it practical for use in evaluating symptoms in men and women-including those aged 65 and over-in the context of research or in clinical practice.
Developed based on qualitative research with patients in multiple countries and cultures and with input from expert clinicians to ensure all clinically relevant concepts were included/retained, the AFSymp TM is a viable alternative to the few existing AF-specific symptom measures. Many existing instruments (e.g., the Symptom Checklist [SCL] [22] , AFSS [23] , AF6 [24] , and AF-QoL [25] ) lack sufficient evidence of content validity based on qualitative research with patients based on current regulatory ''It feels like my heart skips a few beats or something.'' (21) ''Every now and then, my heart does skip a beat-maybe two or three beats. I experienced that yesterday. It wasn't all day long it was just that quick, boom, boom, boom (quickly) and it was over.'' (14) ''It's an arrhythmia … skip beats.'' (242) standards [26] and vary in the level of empirical data available supporting their psychometric properties. Moreover, they do not seem to have been developed cross-culturally, raising the possibility of cultural bias in the concepts included. Recently, the development and validation of the Atrial Fibrillation Effect on Quality-of-Life questionnaire (AFEQT) was reported [27] . Advantages of AFEQT include the rigor of the instrument's development (6) 8 (8) 5 (5) 6 (5) Hispanic American 10 (3) 5 (5) 4 (4) 1 (1) Asian/Oriental/Pacific Islander 3 (1) 2 (2) 1 (1) 0 (0) Other 6 (2) 3 (3) 1 (1) 2 (2) Education, n (%) High school or less 52 (17) 21 (20) 10 (10) 21 (19) High school diploma/GED 105 (34) 32 (31) 35 (35) 38 (34) Some college 48 (15) 12 (12) 20 (20) 16 (14) College degree 69 (22) 27 (26) 20 (20) 22 (20) Graduate/postgraduate 39 (12) 11 (11) 14 (14) 14 (13) Current work status, n (%)
Working (FT/PT) 135 (43) 51 (50) 50 (50) 34 (31) Retired-heart condition 21 (7) 6 (6) 5 (5) 10 (9) Retired-other reason 136 (44) 43 (42) 35 (35) 58 (53) Never employed/other 21 (7) 3 (3) 10 (10) 8 (7) AF episodes during the last month, n (%) Diabetes mellitus 59 (19) 15 (15) 14 (14) 30 (27) Anxiety 47 (15) 21 (20) 10 (10) 16 (15) Heart failure 46 (15) 12 (12) 15 (15) 19 (17) Endocrine disease 37 (12) 15 (15) 9 (9) 13 (12) Pulmonary disease 36 (12) 8 (8) 14 (14) 14 (13) Depression 38 (12) 13 (13) 13 (13) 12 (11) Left ventricular dysfunction 32 (10) 7 (7) 16 ( AF atrial fibrillation, FT full time, GED general educational development, PT part time, SD standard deviation and psychometric evaluation, which followed recommendations in the PRO guidelines issued by the US Food and Drug Administration (FDA) [26] and demonstrated evidence of responsiveness to change. The AFSymp TM also followed contemporary FDA guidelines and consisted of multiple phases of qualitative and quantitative research. Strengths of the AFSymp TM in contrast to existing instruments include the cross-cultural and subgroup-specific approach to development; concurrent testing of content validity in both electronic tablet and paper modes of administration; and utilization of a 1-week recall period. First, the AFSymp TM item generation was informed by research with clinicians and patients in five different countries, ensuring that the items assess concepts AFSymp atrial fibrillation-specific symptom questionnaire, ICC intra-class correlation coefficient, SD standard deviation **p \ 0.01; ***p \ 0.001 a 11-to 14-day window b Week 3 average score-week 2 average score c Spearman rank order correlations that are relevant clinically as well as to patients, use wording patients understand, minimize cultural bias, and facilitate translation and cultural equivalence (i.e., carry the same meaning across countries). Second, in all stages of the development and psychometric validation of the AFSymp TM , care was taken to include equal numbers of patients with paroxysmal, persistent, and permanent AF to ensure validity in all AF subpopulations. Third, administering the questionnaire on an electronic tablet precluded skipped responses; of note, despite the elderly population (mean age 65 [SD 11] years), all patients were able to complete the questionnaire and few had any problems using the touch screen. Finally, the use of a 1-week recall period reflects the patient preference for recall period, allows for a clear recall of the symptom experience, and limits the instrument's vulnerability to response bias, in contrast to other instruments that use longer recall periods (e.g., AFEQT, which uses a 4-week recall period).
Several limitations should be acknowledged. An important weakness of the present study is that it did not permit full evaluation of the responsiveness of the AFSymp TM to treatment changes over time as there was no intervention. Second, two of the items comprising this scale (dizziness and shortness of breath) did not demonstrate adequate factor loadings and, thus, were excluded from the subscale scores and global AFSymp TM score and are recommended for use as descriptive items only. Additionally, only seven of the remaining nine items were found to best represent the global AFSymp TM scale. This scoring algorithm may be less straightforward for clinical use than a simple summation of all of the items; however, given that these items were found to be clinically relevant and important to patients, it was decided to retain the items until further evaluation in intervention studies could be conducted. A third limitation is that, despite conducting qualitative research in multiple countries, the psychometric validation study was conducted in a primarily Caucasian sample in community settings in the US. Lastly, it is possible that additional subgroup analyses to evaluate the performance of this tool (e.g., age, gender), would have been informative. Psychometric validation of the questionnaire in other populations and countries will be essential to confirm the broader validity of the instrument. It should also be noted that while both paper and electronic versions of the questionnaire were tested for acceptability to patients in cognitive interviews, only the electronic version was psychometrically validated.
Conclusion
In conclusion, the AFSymp TM was developed and psychometrically evaluated using rigorous methodology according to FDA guidelines. Initial evidence presented here supports its reliability and validity for use in evaluating symptoms in patients with different subtypes of AF. In the continued preparations for the clinical use of AFSymp TM , documentation of responsiveness of the AFSymp TM over time in patients in whom restoration and maintenance of sinus rhythm is achieved would aid the interpretation of changes in scores in future studies. Additionally, while the AFSymp TM was evaluated using an electronic application, further validation using other electronic media (e.g., web-based versions using tablets, iPhones, Android devices) is needed.
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